NCT00484211View on ClinicalTrials.gov

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

November 30, 2011

Study Completion Date

April 30, 2013

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

NGR-hTNF

iv q3W or q1W 0.8 mcg/sqm NGR-hTNF

Trial Locations (3)

Unknown

Fondazione San Raffaele del Monte Tabor, Milan

Istituto Europeo Oncologico, Milan

Istituto Clinico Humanitas, Rozzano

Sponsors
All Listed Sponsors
lead

AGC Biologics S.p.A.

INDUSTRY